Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)

NCT00295646 is registered in ClinicalTrials.gov with Austrian Breast & Colorectal Cancer Study Group as lead sponsor.

NCT NCT00295646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00295646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)
Lead sponsor
Austrian Breast & Colorectal Cancer Study Group
Phase
Phase 3
Overall status
Completed
Start date
June 30, 1999
Completion date
June 26, 2018
Enrollment
1,803 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer